Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia

Medical and Pediatric Oncology

Volumn 26, Issue 6, 1996, Pages 397-404

  Boos, Joachim ^a,b   Hohenlöchter, Barbara ^a   Schulze Westhoff, Petra ^a   Schiller, Meinhard ^a   Zimmermann, Martin ^a   Creutzig, Ursula ^a   Ritter, Jörg ^a   Jürgens, Herbert ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

cellular pharmacology; cytarabine; cytarabine triphosphate; leukemia; T ALL

Indexed keywords

CYTARABINE TRIPHOSPHATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL STRAIN HL 60; CELL STRAIN K 562; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CONTINUOUS INFUSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; BLOOD CELLS; BONE MARROW; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CULTURE MEDIA; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; IMMUNOPHENOTYPING; INFUSIONS, INTRAVENOUS; INTRACELLULAR FLUID; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, NULL-CELL; LEUKEMIA, T-CELL, ACUTE; NEOPLASM RECURRENCE, LOCAL;

EID: 0029881104     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199606)26:6<397::AID-MPO5>3.0.CO;2-C     Document Type: Article

References (37)

1. Peters WG, Colly LP, Willemze R: High-dose cytosine arabinoside: Pharmacological and clinical aspects. Blut 56:1-11, 1988.
2. Hiddemann W: Cytosine arabinoside in the treatment of acute myeloid leukemia: The role and place of high-dose regimens. Ann Hematol 62:119-128, 1991.
3. Lie SO, Slördahl S: High-dose cytosine arabinoside in the treatment of childhood malignancies. Semin Oncol 12(Suppl 3): 160-165, 1985.
4. van Prooijen HC, Dekker AW, Punt K: The use of intermediate dose cytosine arabinoside (ID ara-C) in the treatment of acute nonlymphocytic leukemia in relapse. Br J Haematol 57:291-299, 1984.
5. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ: Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D- arabinofuranosylcytosine therapy. Cancer Res 47: 3005-3011, 1987.
6. Slcvin ML, Piall EM, Aherne GW, Johnston A, Lister TA: The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med Pediatr Oncol (Suppl 1):157-168, 1982.
7. SlevinML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA: Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1:546-551, 1983.
8. Avramis VI, Weinberg KI, Sato JK, Lenarsky C, Willoughby M, Coates TD, Ozkaynak MF, Parkman R: Pharmacology studies of 1-β-D- arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemical optimal regimen of loading bolus plus continuous infusion of the drug. Cancer Res 49:241-247, 1989.
9. Kessel D, Hall TC, Wodinsky I: Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 156:1240-1241, 1967.
10. Wiley JS, Jones SP, Sawyer WH, Paterson ARP: Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 69:479-489, 1982.
11. White JC, Rathmell JP, Capizzi RL: Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemic cells. J Clin Invest 79:380-387, 1987.
12. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ: Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12(Suppl 1):20-30, 1985.
13. Rustum YM, Preisler HD: Correlation between leukemic cell retention of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy. Cancer Res 39:42-49, 1979.
14. Heinemann V, Estey E, Keating MJ, Plunkett W: Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol 7:622-8, 1989.
15. Bekassy AN, Liliemark J, Garwicz S, Wiebe T, Gullikson H. Peterson C: Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells. Med Pediatr Oncol 18:136-142, 1990.
16. Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Sieges SE, Holcenberg JS: Biochemical pharmacology of high dose 1-β-D-arabinofuranosylcytosine in childhood acute leukemia. Cancer Res 47:6786-6792, 1987.
17. Wörmann B, Anderson JM, Liberty JA, Gajl-Peczalska K, Brunning RD. Silberman TL, Arthur DC, LeBien TW: Establishment of a leukemic cell model for studying human pre-B to B cell differentiation. J Immunol 142:110-117, 1989.
18. Boos J: A simple isocratic ion-pair high-performance liquid chromatographic determination of 1-β-D-arabinofuranosylcytosine 5′-triphosphate for intracellular drug-monitoring and in vitro incubation assays. Pharma Biom Anal 9:47-52, 1991.
19. Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D, Reiter A, Schellong G: Results and significance of six randomized trials in four consecutive ALL-BFM studies. In Büchner T, Schellong G, Hiddemann W, Ritter J (eds):"Haematology and Blood Transfusion, Acute Leukemias 11," Berlin: Springer, 33:439-449, 1990.
20. Henze G, Fengler R, Hartmann R, for the BFM Relapse Study Group: Chemotherapy for relapsed childhood acute lymphoblastic leukemia: Results of the BFM Study Group. In Büchner T, Schellong G, Hiddemann W, Ritter J (eds): "Haematology and Blood Transfusion, Acute Leukemias IV," Berlin: Springer, 36:374-383, 1994.
21. Creutzig U, Ritter J, Zimmermann M, Schellong G: Does cranial irridiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood acute myelogenous leukemia study BFM-87. J Clin Oncol 11:279-286, 1993.
22. Jarvis MS: Nitrobenzylthioinosine-sensitive nucleoside transport system: Mechanism of inhibition by dipyridamole. Mol Pharmacol 30:659-665, 1986.
23. Hiddemann W, Schleyer E, Unterhalt M, Zühlsdorf M, Rolf C, Reuter C, Kewer U, Uhrmeister C, Wörmann B, Büchner T: Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. Leukemia 6:1273-1280, 1992.
24. Rustum YM, Slocum HK, Wang G, Bakshi D, Kelly E, Buscaglia D, Wrzosek C, Early AP, Preisler HD: Relationship between plasma ara-C and intracellular ara-CTP pools under conditions of continuous infusion and high- dose ara-C treatment. Med Pediatr Oncol Suppl 1:33-43, 1982.
25. Plunkett W, Iacoboni S, Keating M: Cellular pharmacology and optimal therapeutic concentrations of 1-β-D-arabinofuranosylcytosine 5′- triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-β-D-arabinofuranosylcytkosine. Scand J Haematol 34(Suppl 44):51-59, 1986.
26. Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W: Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 4:95-99, 1990.
27. Jamieson GP, Snook MB, Wiley JS: Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leuk Res 14:475-479, 1990.
28. Muus P, Drenthe-Schonk A, Haanen C, Wessels H, Linssen P: Invitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells. Leuk Res 11:319-325, 1987.
29. Preisler HD, Rustum YM, Azarnia N, Priore R: Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside. Cancer Chemother Pharmacol 19:69-74, 1987.
30. Momparler RL, Onetto-Pothier N, Bouffard DY, Momparler LF: Cellular pharmacology of 1-β-D-arabinofuranosylcytosine in human myeloid, B- lyphoid and T-lymphoid leukemic cells. Cancer Chemother Pharmacol 27:141-146, 1990.
31. Tanaka M, Yoshida S: Efficient formation of cytosine arabinoside-5′-triphosphate in leukemic blasts of human T-cell acute lymphoblastic leukemia. Leuk Res 13:931-936, 1989.
32. Ross D, Thompson B, Joneckis C, Akman S, Schiffer C: Metabolism of Ara-C by blast cells from patients with ANLL. Blood 68:76-82, 1987.
33. Kawasaki H, Higashigawa M, Ohkubo T, Kamiya H, Sakurai M: Relationship between intracellular dCTP/Ara-CTP ratio and cytotoxic effect of Ara-C. Adv Exp Med Biol 253B:369-74, 1986.
34. Kufe D, Spriggs D, Munroe D: Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 64:54-58, 1984.
35. Ritter J, Creutzig U, Reiter A, Riehm H, Schellong G: Childhood leukemia: Cooperative Berlin-Frankfurt-Münster trials in the Federal Republic of Germany. J Cancer Res Clin Oncol 116:100-103, 1990.
36. Creutzig U, Ritter J. Schellong G for the AML-BFM Study Group. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML- BFM-78. Blood 75:1932-1940, 1990.
37. Lauer SJ, Pinkel D, Buchanan GR, Sartain P, Cornet JM, Krance R, Borella LD, Casper JT, Kun LE, Hoffman RG, Camitta BM: Cytosine arabinoside/cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia - potential selective effect in T-cell leukemia. Cancer 60:2366-2371, 1987.